The indirect benefits of GLP-1 agonists and GIP/GLP1-agonists on cardiovascular and renal risk factors including weight, blood pressure, and lipid profiles are well established; however, their ability to modulate inflammation, fibrosis, and vascular dysfunction through pathways shared with FD highlights their potential as a promising therapeutic avenue for Fabry cardiomyopathy. The gene discussed is GIP; the disease is Fabry disease.